Cell populations which co-express CD49C and CD90

Details for Australian Patent Application No. 2002339977 (hide)

International Classifications

Event Publications

27 February 2003 Complete Application Filed

Priority application(s): 09/960,244 21.09.01 US

5 June 2003 Application Open to Public Inspection

Published as AU-B-2002339977

4 January 2007 Application Accepted

Published as AU-B-2002339977

11 January 2007 Corrigenda

Applications Accepted - Name Index Under the name Neuronyx, Inc., Application No. 2002339977, under INID (72), correct the co-inventor name to Ragaglia, Vanessa

3 May 2007 Standard Patent Sealed

23 April 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

19 November 2009 Section 223 Application Received

Neuronyx, Inc. An application to extend the time from 20 Sep 2008 to 20 Sep 2009 in which to pay a renewal fee has been filed . Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden ACT 2606 2003

21 January 2010 Section 223 Application Allowed

Neuronyx, Inc. the time in which to pay a renewal fee has been extended to 20 Sep 2009. Address for service in Australia - Pizzeys Level 2, Woden Plaza Offices Woden Town Square Woden ACT 2606

11 February 2010 Amendment Made

The nature of the amendment is: Amend the name of the patentee from Neuronyx, Inc. to Garnet BioTherapeutics, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.